Pure Global
NCT06134388

Sulfasalazine in Patients With Metastatic Colorectal Cancer

Clinical Study Evaluating the Efficacy and Safety of Sulfasalazine in Patients With Metastatic Colorectal Cancer
Tanta University·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metastatic Colorectal Cancer
Drug/Device/Intervention
Sulfasalazine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tanta University
Location
Tanta, Egypt
Timeline & enrollment
Phase
Phase 3
Start date
Sep 01, 2023
End date
Sep 01, 2026
Enrollment
50 participants
Primary outcome

Evaluating the change in the serum level of Ferritin,Evaluating the change in the serum level of Superoxide dismutase (SOD),Evaluating the change in the serum level of Nuclear factor-kappa B (NF-kB),Evaluating the change in the serum level of Bcl-2 associated X protein (Bax),Investigating the possible efficacy of sulfasalazine through evaluation of its impact on overall response rate (ORR).,Investigating the possible efficacy of sulfasalazine through evaluation of its impact on disease control rate (DCR).

Summary

The aim of this study is to evaluate the potential efficacy and safety of sulfasalazine in
 patients with metastatic colorectal cancer.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06134388
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06134388 through Pure Global AI's free database. This Phase 3 trial is sponsored by Tanta University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.